The DELIVER Trial
In this medfyle
In the diabetes and cardiology communities, HF with preserved EF is under recognised. In the DELIVER trial, dapagliflozin improved HF outcomes in patients with HF and mildly reduced EF and patients with HF and preserved EF across the spectra of both EF and glycaemia. Following these results, more patient populations must be evaluated who can benefit from SGLT2 inhibitors.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a highlights summary of an oral session given at the EASD Annual Meeting 2022 and presented by:
Dr. Pardeep Jhund
University of Glasgow
Glasgow, UK
Prof. Silvio Inzucchi
Yale School of Medicine
New Haven, CT, USA
Dr. Mikhail Kosiborod
Saint Luke's Mid-America Heart Institute
Kansas City, MO, USA
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
